2017_SBRT_Course Book

Trials on targeted therapies for patients with BM

Entity

n Targeted Therapies Intracranial response rate

OS (months)

NSCLC BM; EGFR status unknown 23 Gefitinib or erlotinib

73,9%

18,8

1-3 BSCLC BM; EGFR status unknown

41 Erlotinib plus WBRT and SRS

NA

6.1

NSCLC BM Alk rearrangement

27 5

Crizotinib Crizotinib plus SRT

56,0% 65,0%

13,2 intra- cranial TTP

HER2-positive breast cancer BM 45 Trastuzumab (T-DM1 ) +chemo plus local therapy Oligosymp. Her2-positiv breast BM 45 Laptinib plus capecitabine

NA

26.8

66,0%

17

BRAF mutated melanoma BM 74 Dabrafenib

39.2%

8,3

BRAF mutated melanoma BM 24 Vemurafenib

42,0%

5,3

Combined strategies may improve antitumor activity

Future of targeted therapy for BM